Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'

The culprit behind price gouging?

In tweets sent out Thursday directed at President-elect Donald Trump, Citron Research targeted pharmacy benefit giant Express Scripts Holding Company ESRX, referring to the company as "the Philidor of the pharma industry," and setting a $45 price target for the stock.

Back in October 2015, the short-seller published a "smoking gun" detailing what it calls a "cover up" concerning Valeant's relationship with specialty pharma company Philidor RX.

An Express Scripts spokesperson told Benzinga, "We clearly disagree with [Left's] assertions. We are not at all like Philidor. Express Scripts is a market force that uniquely puts medicine within reach by driving down cost of care and improving health outcomes."

Since the tweets went out, shares of Express Scripts are down over 6 percent at $69.36.

CVS Health Corp CVS also fell, trading recently at $77.97, down 3 percent.